Novo Nordisk's $1 billion bet last year on a small Canadian biotech could expand the Danish drug giant's arsenal of obesity medicines, but it will first have to address safety concerns. On Friday, Nov ...
Novo Nordisk fell more than 4% on Friday to their lowest level since Aug. 10 after the Danish drugmaker reported results from ...
A next-generation obesity drug candidate from Novo Nordisk produced modest weight loss, along with a higher rate of some ...
Novo Nodrisk’s cannabinoid receptor–targeting obesity pill was picked up in the $1.1 billion acquisition of Inversago ...
52mon MSN
Novo Nordisk’s obesity drug Wegovy is now recommended by EU regulatory authorities for obesity-related heart conditions.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback